tartrate-resistant acid phosphatase

Neomangiferin (Mangiferin 7-glucoside) has beneficial effects on high fat diet-induced nonalcoholic fatty liver disease in rats. Neomangiferin and mangiferin inhibit tartrate-resistant acid phosphatase, a biochemical marker of osteoclast function and bone resorption.

AubipyOMe serves as an effective inhibitor of Tartrate-resistant Acid Phosphatase (TRAP/ACP5), a metalloenzyme identified in activated osteoclasts and macrophages. It exhibits inhibitory IC50 values of 1.3 μM against TRAP5a and 1.8 μM against TRAP5b. Additionally, it effectively suppresses TRAP activity in extracts from mouse macrophages and human lung tissues.

CBK289001 is a tartrate-resistant acid phosphatase (TRAP/ACP5) inhibitor that inhibits TRAP 5b MV, TRAP 5b OX, and TRAP 5a OX with IC50 values of 125 μM, 4.21 μM, and 14.2 μM, respectively.

Morusignin L is a biologically active prenylated flavonoid compound that has been demonstrated to exhibit significant anti-osteoporosis effects in vitro, potentially mediated through the inhibition of osteoclast tartrate-resistant acid phosphatase (TRAP) enzyme activity and bone resorption, coupled with the concurrent promotion of osteoblast proliferation and differentiation.

Neomangiferin (Standard) is a reference standard for research and analysis in studies involving Neomangiferin. Neomangiferin (Mangiferin 7-glucoside) has beneficial effects on high fat diet-induced nonalcoholic fatty liver disease in rats. Neomangiferin and mangiferin inhibit tartrate-resistant acid phosphatase, a biochemical marker of osteoclast function and bone resorption.